Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Authors :: Jonathan A. Gutman
Amanda C. Winters
Andrew Kent
Maria L. Amaya
Christine M. McMahon
Clayton Smith
Craig T Jordan
Brett M. Stevens
Mohammad Minhajuddin
Shanshan Pei
Jeffrey Schowinsky
Jennifer Tobin
Kelly O'Brien
Angela Falco
Elizabeth Taylor
Constance Brecl
Phuong Ho
Connor Sohalski
Jessica Dell-Martin
Olivia Ondracek
Diana Abbott
Daniel A. Pollyea
Source :: Blood. 140:3275-3276
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools